| Literature DB >> 35282934 |
Abstract
Platinum-based chemotherapy forms the backbone of treatment for many solid cancers. However, resistance inevitably develops in those with advanced disease. Platinum rechallenge is a well-established concept in the management of ovarian cancer, small cell lung cancer and germ cell tumours. In other solid malignancies there is a lack of quality evidence to support platinum rechallenge, yet it is a widely adopted strategy. Often, patients are within the last year of life, making questions of efficacy, treatment-related toxicity and quality of life critical factors for treatment recommendations. In this overview we appraise the available evidence for platinum rechallenge and strategies being developed to attempt resensitisation of tumours to platinum-based chemotherapy.Entities:
Keywords: Carboplatin; chemotherapy; cisplatin; rechallenge; resistance
Mesh:
Substances:
Year: 2022 PMID: 35282934 DOI: 10.1016/j.clon.2022.02.015
Source DB: PubMed Journal: Clin Oncol (R Coll Radiol) ISSN: 0936-6555 Impact factor: 4.925